Acta Haematol. 2012;127(3):135-42. Epub 2012 Jan 12.

International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: first report from India.

Balasubramanian P, Chendamarai E, Markose P, Fletcher L, Branford S, George B, Mathews V, Chandy M, Srivastava A.

Source

Department of Haematology, Christian Medical College, Vellore, India. bpoonkuzhali@cmcvellore.ac.in

Abstract

Achieving a major molecular response (MMR) is an important predictor of progression-free survival in chronic myeloid leukemia patients treated with imatinib. This requires accurate measurement of BCR-ABL1 transcripts normalized to a control gene, as well as defining a level (BCR-ABL1/control gene ratio) that will correlate with sustained clinical response. To make these measurements comparable between laboratories, an international scale (IS) is necessary. A BCR-ABL1/control gene ratio of 0.10% represents MMR in the IS. In collaboration with an international reference laboratory in Adelaide, S.A., Australia, we have established and validated a lab-specific conversion factor for expressing BCR-ABL1 transcript levels in the IS. In this report, we explain the process and steps involved in obtaining a valid lab-specific conversion factor for expressing BCR-ABL1 transcript levels in the IS.

PMID:: 22249155; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Medical

Chronic Myeloid Leukemia - MedlinePlus Health Information

Molecular Biology Databases

IMATINIB MESYLATE - HSDB

Supplemental Content

Icon for S. Karger AG, Basel, Switzerland

Save items

Related citations in PubMed

BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. [Clin Cancer Res. 2007]
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K, Hughes T. Clin Cancer Res. 2007 Dec 1; 13(23):7080-5.
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. [Clin Cancer Res. 2007]
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
Press RD, Galderisi C, Yang R, Rempfer C, Willis SG, Mauro MJ, Druker BJ, Deininger MW. Clin Cancer Res. 2007 Oct 15; 13(20):6136-43.
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. [Leukemia. 2010]
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, Slader C, Field C, Dang P, Filshie RJ, et al. Leukemia. 2010 Oct; 24(10):1719-24. Epub 2010 Sep 2.
Review Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. [Blood Rev. 2006]
Review Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.
Hughes T, Branford S. Blood Rev. 2006 Jan; 20(1):29-41. Epub 2005 Mar 2.
Review Chronic myelogenous leukemia: monitoring response to therapy. [Curr Hematol Malig Rep. 2011]
Review Chronic myelogenous leukemia: monitoring response to therapy.
Branford S, Prime J. Curr Hematol Malig Rep. 2011 Jun; 6(2):75-81.

See reviews... See all...

Recent activity

Clear Turn Off Turn On

International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid l...
International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: first report from India.
Acta Haematol. 2012 ;127(3):135-42. Epub 2012 Jan 12 .

PubMed
Parvovirus B19 in pregnancy: prenatal diagnosis and management of fetal complic...
Parvovirus B19 in pregnancy: prenatal diagnosis and management of fetal complications.
Curr Opin Obstet Gynecol. 2012 Mar ;24(2):95-101.

PubMed
Outcomes in severe sepsis and patients with septic shock do not matter! PIRO is ...
Outcomes in severe sepsis and patients with septic shock do not matter! PIRO is a score to treat severe septic and septic shock patients not to measure outcomes.
Crit Care Med. 2012 Feb ;40(2):706-7; author reply 707-8.

PubMed
The intensive care unit continuum of care: easing death.
The intensive care unit continuum of care: easing death.
Crit Care Med. 2012 Feb ;40(2):700-1.

PubMed
A risk-adapted strategy of adjuvant paclitaxel/carboplatin in early-stage ovaria...
A risk-adapted strategy of adjuvant paclitaxel/carboplatin in early-stage ovarian cancer: time-dependent effect of 4 versus 6 cycles on outcome.
Oncology. 2011 ;81(5-6):365-71. Epub 2012 Jan 13 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: first report from India.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information